TITLE

Simponi

PUB. DATE
July 2009
SOURCE
Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. It notes that the drug treats rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. It is considered as the first patient-administered anti-tumor necrosis factor (TNF)-alpha therapy.
ACCESSION #
42732613

 

Related Articles

  • J&J: Simponi's triple US approval could be first step towards blockbuster status.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p21 

    In this article the author discusses the approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. by the U.S. Food and Drug Administration (FDA). It is a new tumor necrosis factor (TNF) inhibitor for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. He mentions that...

  • Centocor and Schering-Plough win Canadian approval for arthritis drug.  // PharmaWatch: Biotechnology;Nov2009, Vol. 8 Issue 11, p17 

    The article reports that Health Canada has granted approval of Simponi as therapy for active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS) by Centocor Ortho Biotech Inc. and Schering-Plough Corp. The approval of the drug is based from five...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Jun2009 Pharmacology Watch, p2 

    The article reports on several U.S. Food and Drug Administration drug approval as of June 2, 2009. A U.S. district judge ruled in March for the drug Plan B, the so-called "morning after pill" to be made available to women age 17. The agency has approved golimumab, a tumor necrosis factor-alpha...

  • Centocor Ortho Biotech's Simponi Gains Approval. Young, Donna // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p2 

    The article reports on the approval of Simponi, an antitumor necrosis factor (TNF)-alpha therapy of Centocor Ortho Biotech Inc., by the U.S. Food and Drug Administration (FDA). The therapy is a patient-administered monthly treatment for moderate to severe active rheumatoid arthritis, active...

  • TNF-blocker triple approval. Netterwald, James // Nature Biotechnology;Jun2009, Vol. 27 Issue 6, p495 

    The article reports on the approval of Simponi-branded golimumab by the U.S. Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Simponi, a tumor necrosis factor alpha (TNF-α) blocker manufactured by Johnson & Johnson's...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Jun2009 Pharmacology Watch, p2 

    The article presents an update on U.S. Food and Drug Administration (FDA) actions in 2009. A morning after pill called Plan B from Duramed Pharmaceuticals will be available to women age 17 and older without a prescription following a court order directing the FDA to evaluate clinical data to...

  • Golimumab.  // Australian Prescriber;Feb2010, Vol. 33 Issue 1, p23 

    The article discusses Golimumab, a new drug released in the Australian pharmaceutical market with approved use in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is described as a recombinant human monoclonal antibody that blocks the activity of tumour...

  • MUSCULOSKELETAL DISORDERS.  // Nurse Practitioners Prescribing Reference;Winter2009/2010, Vol. 16 Issue 4, p190 

    The article offers information on prescriptions of various drugs to treat musculoskeletal disorders. Ansaid from Pfizer Inc. is prescribed to treat rheumatoid arthritis and osteoarthritis which requires 200-300 milligrams (mg)/day in 2-4 divided doses. Simponi from Centocor Ortho Biotech Inc. is...

  • FDA Approves Biologic to Treat Psoriasis.  // BioPharm International;Nov2009, Vol. 23 Issue 11, p14 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Stelara from Centocor Ortho Biotech Inc. to treat psoriasis. It notes that the drug blocks the action of two proteins contributing to the overproduction of skin cells and inflammation. It points out that FDA...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics